Aktienanalyse wird geladen …
COO · NASDAQ · Medical Instruments & Supplies · USA
55,38 $
| Geschäftsjahr | Umsatz | Nettogewinn | EPS (GAAP) | Aktien (verw., gesamt) | SBC in Stück | Rückkäufe (ca.) | Bruttomarge | Nettomarge | FCF / Aktie | SBC / Aktie | Dividende / Aktie |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | 4,09 Mrd. | 374,9 Mio. | 1,87 $ | 200 Mio. | 1,3 Mio · 0,6 % | 1,7 Mio · 0,8 % | 65,5 % | 9,2 % | 2,17 $ | 0,35 $ | — |
| 2024 | 3,9 Mrd. | 392,3 Mio. | 1,96 $ | 200,4 Mio. | 1,4 Mio · 0,7 % | 0,3 Mio · 0,1 % | 66,6 % | 10,1 % | 1,44 $ | 0,37 $ | 0,00 $ |
| 2023 | 3,59 Mrd. | 294,2 Mio. | 1,48 $ | 199,3 Mio. | 1,1 Mio · 0,6 % | 0,6 Mio · 0,3 % | 65,6 % | 8,2 % | 1,08 $ | 0,31 $ | 0,01 $ |
| 2022 | 3,31 Mrd. | 385,8 Mio. | 1,94 $ | 198,8 Mio. | 1 Mio · 0,5 % | 1,4 Mio · 0,7 % | 64,7 % | 11,7 % | 2,27 $ | 0,27 $ | 0,01 $ |
| 2021 | 2,92 Mrd. | 2,94 Mrd. | 14,79 $ | 199,2 Mio. | 0,8 Mio · 0,4 % | — | 66,9 % | 100,8 % | 2,63 $ | 0,22 $ | 0,03 $ |
| 2020 | 2,43 Mrd. | 238,4 Mio. | 1,20 $ | 198,4 Mio. | 0,7 Mio · 0,3 % | 2,3 Mio · 1,1 % | 63,1 % | 9,8 % | 0,89 $ | 0,19 $ | 0,03 $ |
| Quartal | Umsatz | Nettogewinn | EPS | Aktien (verw., gesamt) | Bruttomarge | Nettomarge | FCF / Aktie |
|---|---|---|---|---|---|---|---|
| Q3 2026 | 1,07 Mrd. | 432,8 Mio. | 2,24 $ | 193,4 Mio. | 66,8 % | 40,6 % | 1,41 $ |
| Q2 2026 | 1,08 Mrd. | -77,9 Mio. | -0,40 $ | 195 Mio. | 68 % | -7,2 % | 0,49 $ |
| Q1 2026 | 1,02 Mrd. | 130,8 Mio. | 0,66 $ | 196,7 Mio. | 67,9 % | 12,8 % | 0,81 $ |
| Q4 2025 | 1,07 Mrd. | 84,6 Mio. | 0,43 $ | 198,1 Mio. | 61,1 % | 7,9 % | 0,75 $ |
| Q3 2025 | 1,06 Mrd. | 98,3 Mio. | 0,49 $ | 200 Mio. | 65,3 % | 9,3 % | 0,82 $ |
| Q2 2025 | 1 Mrd. | 87,7 Mio. | 0,44 $ | 200,7 Mio. | 67,8 % | 8,8 % | 0,09 $ |
| Q1 2025 | 964,7 Mio. | 104,3 Mio. | 0,52 $ | 201,2 Mio. | 68,4 % | 10,8 % | 0,50 $ |
| Q4 2024 | 1,02 Mrd. | 117,5 Mio. | 0,59 $ | — | 66,6 % | 11,5 % | 0,64 $ |
COO Unveils New Innovation Hub & Lens Launch Plans to Aid CooperVision
CooperCompanies (COO) Keeps CooperSurgical and Expands Buybacks. What Did the Strategic Review Reveal?
CooperCompanies Unveils Accelerated CooperVision Innovation Strategy at The Vision Centre Opening
CooperVision Powers the Next Era of Eye Care with New Global Vision Centre and Major Pipeline Advancements
CooperVision Powers the Next Era of Eye Care with New Global Vision Centre and Major Pipeline Advancements
CooperVision Powers the Next Era of Eye Care with New Global Vision Centre and Major Pipeline Advancements
Activist investor urges Cooper Companies to replace CEO, sell some assets
The Cooper Companies, Inc. is a global medical device company focused on vision care and women’s health. Through its CooperVision segment, the company develops, manufactures, and markets a broad range of contact lenses, including daily disposable, toric, multifocal, and specialty products designed to support different vision correction needs. Its CooperSurgical segment provides fertility, reproductive health, and women’s healthcare products and services, including medical devices, diagnostic tools, cryostorage solutions, and office-based surgical products. The Cooper Companies serves eye care professionals, fertility clinics, hospitals, and other healthcare providers across international markets. Headquartered in San Ramon, California, The Cooper Companies, Inc. plays an important role in specialized healthcare by combining consumer-facing vision products with clinical solutions for reproductive and women’s health.
WebsiteMit einem Konto testest du Glancefield Pro 3 Tage gratis und bewertest COO und jede andere Aktie unbegrenzt.